Table 2:

Mean (SD) in vitro aerosol drug delivery using the original LFNC delivery components as developed in Farkas et al. (2018) applied to the NMT model under steady state inhalation and cyclic breathing conditions. Values are reported as a percentage of nominal dose loaded into the capsule. Standard deviations (SD) shown in parenthesis [n=3].

Description	Steady State	Deep Nasal	Passive Nasal
Capsule (%)	13.9 (7.5)	17.1 (4.1)	19.6 (5.2)
Device (%)	2.4 (0.2)	3.3 (0.6)	3.1 (0.3)
Device ED (%)	83.7 (7.4)	79.6 (4.3)	77.3 (5.0)
Spacer (%)	6.6 (0.9)	6.1 (0.4)	7.3 (1.5)
Y Retention (%)	4.5 (1.1)	3.6 (0.6)	3.5 (0.9)
Tubing Retention (%)	5.8 (0.8)	4.5 (2.1)	4.5 (2.1)
Cannula Retention (%)	4.9 (2.1)	4.1 (1.4)	3.6 (1.9)
Cannula Emitted (%)	61.9 (2.8)	61.3 (0.8)	58.5 (1.4)
NMT (%)	4.6 (1.5)	6.0 (1.9)	3.6 (1.3)
Filter Delivery (%)	50.9 (3.0)	46.9 (1.0)	46.4 (3.5)
Recovery (%)	93.6 (1.2)	91.6 (3.3)	91.5 (3.9)